Repetitive Transcranial Magnetic Stimulation in Early Psychosis and The Functional Connectivity Biotypes

Launched by SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE · Apr 18, 2021

Keywords

ClinConnect Summary

This clinical trial is studying a treatment called repetitive transcranial magnetic stimulation (rTMS) for people experiencing early signs of psychosis, such as schizophrenia or those at high risk for developing psychosis. The researchers want to see how effective this treatment is and how it connects to the brain's activity in these individuals. The trial is currently looking for participants between the ages of 14 and 45 who meet certain criteria, including specific symptoms that indicate a high risk for psychosis or a first episode of schizophrenia.

If you or someone you know is interested in participating, they will have to go through an interview to confirm eligibility and provide written consent. Participants may also be receiving other medications for their condition. Throughout the trial, they can expect to undergo rTMS treatments, which are non-invasive and involve sending magnetic pulses to the brain. It's important to note that there are certain health conditions and recent substance use that may exclude someone from joining the study. This trial aims to better understand how rTMS may help those facing early psychotic symptoms and contribute to future treatments.

Gender

ALL

Eligibility criteria

• • For subjects at clinical high-risk for psychosis
• Inclusion Criteria:
• • Meeting the syndrome of clinical high risk of psychosis, identified by a face-to-face interview using the Chinese version of Structured Interview for Prodromal Syndromes / Scale of Prodromal Symptoms (SIPS/SOPS);
• • Given the written consent for participation.
• • Age between 14-45 years old;
• • IQ\>69;
• • PANSS total scores \>= 55 or BVMT-R score \<= 26;
• Exclusion Criteria:
• • any contraindication to TMS treatment or magnetic resonance imaging (MRI)
• • substance or alcohol abuse within recent three months
• • any sensorimotor disorder (e.g., hearing disorder, lose one's sight), or any neurological disease (brain injury, epilepsy ) or any other physical disease which may lead to psychotic symptoms.
• • For subjects with first-episode schizophrenia
• Inclusion Criteria:
• • Meeting the DSM-V diagnostic criteria for schizophrenia spectrum disorders;
• • Given the written consent for participation.
• • Age between 14-45 years old;
• • IQ\>69;
• • during the first episode without a full remission;
• • PANSS total scores \>= 55 or BVMT-R score \<= 26;
• • within receiving rTMS, patients can receive second-generation antipsychotics except clozapine with stable dosages
• Exclusion Criteria:
• • any contraindication to TMS treatment or magnetic resonance imaging (MRI)
• • substance or alcohol abuse within recent three months
• • any sensorimotor disorder (e.g., hearing disorder, lose one's sight), or any neurological disease (brain injury, epilepsy) or any other physical disease which may lead to psychotic symptoms.